T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + Rilvegostomig
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Conditions
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Trial Timeline
Mar 9, 2021 → Jun 30, 2027
NCT ID
NCT04686305About T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + Rilvegostomig
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + Rilvegostomig is a phase 1 stage product being developed by Daiichi Sankyo for Locally Advanced or Metastatic Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04686305. Target conditions include Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04686305 | Phase 1 | Recruiting |
Competing Products
20 competing products in Locally Advanced or Metastatic Non-Small Cell Lung Cancer